USPTO serial 99024523
ZEPP
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- LAVOIE, RYAN CHRISTOPHER
- Law office
- TMEG LAW OFFICE 108
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ZEPP?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
King of Prussia, PA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Scott Woldow
Scott Woldow Smith, Gambrell & Russell, LLP1055 Thomas Jefferson Street, NWWashington, DC 20007United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Electronic data collection and data submission services for business purposes in the fields of medicine, healthcare and related research; Providing an on-line database providing business intelligence in the fields of medical devices, pharmaceuticals and life sciences; Providing business intelligence services in the fields of pharmaceuticals and the life sciences. | ACTIVE | — |
| 040 | Biomanufacturing for others, namely, manufacturing of pharmaceuticals; custom biomanufacturing of biological preparations; Custom manufacture of pharmaceuticals; Custom manufacturing services, namely, fractionation services for others. | ACTIVE | — |
| 042 | Scientific, pharmaceutical and medical research and development; biological research; Platform as a Service {PAAS} services featuring software for scientific research, pharmaceutical research, and medical research for reviewing, organizing and displaying research information in the field of bioproduction and regulatory pathway services; Research on the subject of pharmaceuticals; Pharmaceutical drug development services; Pharmaceutical research and development; Pharmaceutical products development; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Conducting early evaluations in the field of new pharmaceuticals; pharmaceutical product evaluation; Research and development services relating to pharmaceuticals and medicines; development of pharmaceutical preparations and medicines; Providing medical and scientific research information in the fields of pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Consulting services in the field of pharmaceutical and medicinal research; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of biotechnology; Consulting services in the field of pharmaceuticals, biopharmaceuticals, and fractionation. | ACTIVE | — |
| 045 | Regulatory compliance consulting in the field of biotechnology; Regulatory compliance consulting in the field of pharmaceuticals; Providing Information about legal eligibility requirements for government medical and pharmaceutical programs; Regulatory and legal process pathway consulting for clinical manufacturing. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 1, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 1, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 1, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 31, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Aug 3, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Feb 3, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Feb 3, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Feb 3, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jan 12, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 12, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 12, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 13, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Oct 13, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jul 11, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 11, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 11, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 11, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 2, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 31, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 31, 2025 | NWAP | NEW APPLICATION ENTERED | — |